For individuals in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, and Tennessee, who paid for the cancer treatment drugs Thalomid or Revlimid before Aug. 1, 2019, then you are eligible for a potential award from the Celgene Class Action Lawsuit!
According to the International Myeloma Foundation, Thalomid is an immunomodulatory drug. This means that the drug affects the immune system and, in conjunction with other medications, is considered an effective treatment for multiple myloma — the first in decades when it was introduced in 2006, according to the Foundation.
Celgene denies any wrongdoing, but has agreed to pay $55 million to end the Thalomid, Revlimid antitrust class action lawsuit. So if you are eligible, file a claim by December 2, 2019 to receive your potential award!
Celgene’s Lawsuit
- Celgene’s Thalamoid Claim Form
- Claim Form Deadline: December 2, 2019
- Who’s Eligible: Class Members include both individuals, insurance, and other health and welfare companies who “paid for all or some of the purchase price of Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before August 1, 2019.
- Estimated Amount: Varies. Claims will vary depending on the purchases of the Class Member.
- Proof of Purchase: Not required at this time. However, the settlement administrator may ask for proof later on.
- Case Name & Number: In re: Thalomid and Revlimid Antitrust Litigation, Case No. 2:14-cv-06997, in the U.S. District Court for the District of New Jersey
How To File a Claim
- Head over to the Celgene’s Claim Form.
- Look over the claim form to see if you are eligible.
- Complete the claim form with your information.
- Submit your claim by December 2, 2019 to receive your potential award!
Bottom Line
For individuals in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, and Tennessee, who paid for the cancer treatment drugs Thalomid or Revlimid before Aug. 1, 2019, then you are eligible for a potential award from the Celgene Class Action Lawsuit!
According to the International Myeloma Foundation, Thalomid is an immunomodulatory drug. This means that the drug affects the immune system and, in conjunction with other medications, is considered an effective treatment for multiple myloma — the first in decades when it was introduced in 2006, according to the Foundation. So if you are eligible, file a claim by December 2, 2019 to receive your potential award!
Don’t forget to take a look at our full list of Class Action Lawsuit Settlements!
(Click here to file a claim form)
